Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like Two NIH Sources Reveal is Considering New Cuts to Biomedical Research May 18, 2017 Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017 Genentech's Oncology Boss Jumps Ship to Helm Bellicum January 30, 2017
Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017
